Previous 10 | Next 10 |
2024-01-11 04:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range Announced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025 NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ...
2023-12-24 21:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6 th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Ph...
2023-11-13 09:51:59 ET More on Royalty Pharma, Teva, etc. Royalty Pharma: Post Q3 Earnings, We Reiterated Our Strong Buy Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 Teva Pharmaceuticals Internation...
2023-11-12 05:05:51 ET Summary Royalty Pharma shows solid financial performance and increases its 2023 guidance. New Evrysdi transaction to grow adjusted cash receipts and diversify the company's risks. Better MIX of approved drugs and late development-stage therapies. Com...
2023-11-08 12:57:03 ET Royalty Pharma PLC (RPRX) Q3 2023 Earnings Conference Call November 08, 2023, 08:00 ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairm...
2023-11-08 08:48:36 ET More on Royalty Pharma Royalty Pharma: The Time Has Come Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone Royalty Pharma Q3 2023 Earnings Preview Royalty Pharma to buy up to $1.5B of PTC Therapeutics’ roy...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...